ADC Therapeutics SA (ADCT) is a leading oncology-focused biotechnology company that specializes in the development and commercialization of highly potent and targeted antibody-drug conjugates (ADCs) for patients battling hematologic cancers and solid tumors. The firm's ADCs are a class of medications designed to harness the targeting ability of monoclonal antibodies by linking them to cell-killing agents.
The company's headquarters are in Switzerland, but it has additional offices in London, San Francisco, New Jersey, and New York, enabling it to carry out operations and research globally. Notably, ADC Therapeutics has a state-of-the-art laboratory in London where it carries out its research activities.
ADCT has established a strong portfolio in the pharmaceutical market. Its lead product, Lonca (loncastuximab tesirine), received accelerated approval from the U.S. Food and Drug Administration (FDA) in April 2021 for treatment of relapsed or refractory diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma.
ADC Therapeutics is continuously working on advancing its pipeline of proprietary ADCs with multiple ongoing clinical trials. Another one of its product candidates, Cami (camidanlumab tesirine) has demonstrated antitumor activity in a pivotal Phase 2 clinical trial for patients with relapsed or refractory Hodgkin lymphoma and is nearing potential commercialization.
Apart from Lonca and Cami, the company has multiple other ADCs in advanced clinical development which target different types of cancers. The company's pipeline demonstrates its commitment to revolutionize cancer treatment.
Innovation is core to the company's strategy, as it continues to develop advanced ADCs that can cater to various hematologic cancers and solid tumors. ADC Therapeutics thrives on a diverse, multinational workforce who shares their expertise and dedication toward the common goal of improving patients’ lives.
ADC Therapeutics SA (ADCT) is a publicly traded company, with its shares listed on the New York Stock Exchange. With a market cap in the billions, the company's work and future potential are recognized and backed by substantial investors worldwide.
Through its innovative drugs and dedication to cancer treatment, ADC Therapeutics is poised to make a significant global impact in oncology. Their vision is to leverage the full power of ADCs and become the leading developer in this vital sector of pharmaceutical research and development.